Antony Loebel, MD

  • 12Articles
  • 94.2KReads
  • 2006–2023Active
  • 48Collaborators
  • 492Citations

About

Antony Loebel, MD, is affiliated with Sunovion Pharmaceuticals Inc. in Teaneck, New Jersey, and Marlborough, Massachusetts. Since 2006, Dr. Loebel has published extensively on the treatment of schizophrenia, schizoaffective disorders, bipolar disorder, major depressive disorder, eating disorders, sexual dysfunction, and sleep. His work includes clinical studies on the efficacy and safety of pharmacologic treatments such as lurasidone, dasotraline, and ziprasidone across various psychiatric conditions. Dr. Loebel has frequently collaborated with co-authors including Andrei Pikalov, Josephine Cucchiaro, Leslie Citrome, Hans Kroger, and Jay Hsu.

Publications

JCP
Lurasidone and Anxiety Symptoms in Bipolar Depression
Original Research

Lurasidone and Anxiety Symptoms in Bipolar Depression

June 7, 2023

Lurasidone was superior to placebo at reducing anxiety in bipolar depression. Change in anxiety symptoms was predicted by sleep disturbance at baseline.
, , , et al
JCP
Original Research

Dasotraline and Binge-Eating Treatment

September 8, 2020

Read a study evaluating dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, in treating adults with binge-eating disorder (BED).
, , , et al
JCP
Original Research

Lurasidone and Sexual Function

August 7, 2018

As you probably know, sexual dysfunction is a common side effect of antidepressants and antipsychotics. This secondary analysis of an RCT examines whether the atypical antipsychotic lurasidone was linked...
, , , et al
PCC
Article

Patient Characteristics With Antipsychotic Treatment

June 1, 2017

How does lurasidone compare to other atypical antipsychotics for treatment of bipolar disorder? This study assessed background characteristics, comorbidities, prior health care utilization, and costs for patients with bipolar...
, , , et al
JCP
Original Research

Lurasidone in Early Nonresponding Schizophrenia

December 28, 2016

What's the next step when a patient doesn' t respond to an antipsychotic? Should you augment, switch medications, wait and see, or raise the dose? Read this study in...
, , , et al
JCP
Original Research

Lurasidone in Older Adults With Bipolar Depression

October 26, 2016

Lurasidone's favorable safety profile in younger adults suggests it would be a good candidate for the treatment of episodes of bipolar depression in older adults. For your patients 55...
, , , et al
JCP
Original Research

Lurasidone and Bipolar Depression

April 22, 2015

Read the analysis of a randomized placebo-controlled trial of Lurasidone in the Treatment of Bipolar Depression With Mixed (Subsyndromal Hypomanic) Features.
, , , et al
JCP
Original Research

Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study

March 13, 2013

, , , et al
JCP
Original Research

Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics: A Randomized, 6-Week, Open-Label Study

January 15, 2013

, , , et al
JCP
Original Research

Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial

June 2, 2009

, , , et al
JCP
Original Research

Efficacy and Tolerability of Adjunctive Ziprasidone in Treatment-Resistant Depression: A Randomized, Open-Label, Pilot Study

July 16, 2007

, , , et al
JCP
Original Research

Efficacy of Ziprasidone Against Hostility in Schizophrenia: Post Hoc Analysis of Randomized, Open-Label Study Data

April 15, 2006

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe